Financial Data and Key Metrics Changes - Research and development expenses increased to approximately $1,400,000 for Q2 2025 from approximately $800,000 in Q2 2024, and increased to approximately $2,900,000 for the six months ended June 2025 from $2,800,000 in the same period of 2024 [16] - Selling, general and administrative expenses decreased to approximately $700,000 in Q2 2025 from approximately $900,000 in Q2 2024, while remaining consistent at approximately $1,900,000 for the six months ended June 2025 compared to the same period in 2024 [16] - Net loss was approximately $2,000,000 for Q2 2025 compared to approximately $1,600,000 for Q2 2024, and approximately $4,800,000 for the six months ended June 2025 compared to approximately $3,900,000 for the same period in 2024 [17] - Cash and cash equivalents totaled $980,000 at the end of the quarter, with a current cash balance of approximately $1,100,000 after selling $769,000 in common stock [18] Business Line Data and Key Metrics Changes - The CardioAmp heart failure trial showed a lower incidence of all-cause death and non-fatal MACE in the treatment group compared to the control group, with a p-value of 0.17, and a statistically significant composite endpoint in patients with elevated NT proBNP with a p-value of 0.02 [6][9] - The CARDI Amp cell therapy in chronic myocardial ischemia (BCDO2) is expected to deliver final top-line data in Q4 2025 [14] - The Helix Biotherapeutic delivery system is anticipated to be submitted for FDA approval in Q3 2025 [15] Market Data and Key Metrics Changes - Japan's PMDA has shown interest in heart failure therapy, with the company expecting to align on pathways for therapy availability [7] - The company is preparing for a meeting with the FDA regarding the approvability of the CardiAmp system based on clinical data [9] Company Strategy and Development Direction - The company aims to partner its Helix delivery system for the cardiac electrophysiology market and is focused on creating value through partnerships across its four platforms: CardiAmp, CardiAllo, Helix, and MorphDNA [11][12] - The company is actively pursuing distribution partnerships in Japan and the U.S. for its therapies, emphasizing the cultural alignment of its autologous cell therapy with Japanese preferences [23][40] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the upcoming regulatory meetings with PMDA and FDA, highlighting the potential for approval based on compelling clinical data [35] - The company is focused on maintaining a low burn rate while advancing multiple trials and regulatory submissions, with an annual burn rate of approximately $6,000,000 [76] Other Important Information - The company is preparing a peer-reviewed manuscript based on the data presented at the American College of Cardiology, which will be accessible to the public [70] - The company is working on a financing event that aims to be beneficial for current shareholders, with a focus on minimizing dilution [73] Q&A Session Summary Question: Expectations regarding PMDA reviewing Cardium for heart failure as a medical device - Management indicated that the approval process is viewed as a lower hurdle for medical device approval, with a focus on the clinical consultation process [20][21] Question: Timing for the Cardium CMI program data - Management confirmed that the rolling cohort data related to primary endpoint results is expected in Q4 [26] Question: Timing of regulatory meetings and potential outcomes - If meetings go well, the approval process could take up to a year, with parallel efforts on reimbursement and distribution partnerships [32][34] Question: Status of FDA meeting type and HF2 trial screening - Management is contemplating the type of FDA meeting and confirmed that the HF2 trial is actively enrolling patients with a focus on compliance and stability [45][50] Question: Expectations following data readout for BCDA - Management stated that outcomes depend on PMDA and FDA responses, with potential for non-dilutive capital to accelerate the BCDA program [60] Question: Release of new data observations to the public - Management confirmed that a peer-reviewed manuscript will be prepared to share data observations, while also working on regulatory submissions [70] Question: Details on the upcoming financing event - Management emphasized the importance of a financing event that minimizes dilution and supports ongoing trials and partnerships [73][75]

Financial Data and Key Metrics Changes - The company generated approximately $300 million in revenue and adjusted EBITDA of $17.2 million in Q2 2025, with adjusted EBITDA up by $1 million compared to the same quarter last year despite an 11% decline in revenue [11] - Total adjusted SG&A expenses were $64.9 million, representing 77.4% of gross profit, down from $70.8 million and 78.8% of gross profit in the same quarter last year, indicating an 8.3% reduction [11] Business Line Data and Key Metrics Changes - The power sports group sold 17,117 total major units, down 3.3% year-over-year, with new unit sales down 11.5% and pre-owned unit sales up 10.2% [12] - Revenue from parts, services, and accessories was $52.4 million, a 7.9% decline, while gross profit was $24.9 million, down 5% [13] - Financing and insurance teams generated $27.2 million in gross profit, reflecting an 8.4% decline compared to the previous year [13] Market Data and Key Metrics Changes - Revenue from the powersports dealership group was $298.6 million, down 7.2% year-over-year, while gross profit was $83.7 million, down 3.6% [14] - Wholesale Express revenue was $1.3 million, a significant decline of 91.4% compared to the same quarter last year, with gross profit decreasing by 93.5% to $200,000 [15] Company Strategy and Development Direction - The company is rebranding to Ride Now Group Inc., with a focus on simplifying operations and aligning corporate and store functions to enhance customer service [8] - A term loan amendment extended maturity by 13 months to September 30, 2027, providing necessary runway for business improvement initiatives [10][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the current pricing environment, indicating that the industry appears to have bottomed out and is beginning to show signs of recovery [21][22] - The company is focused on rebuilding the Wholesale Express sales force and exploring new B2C opportunities, indicating a strategic shift in operations [25][26] Other Important Information - The company ended the quarter with $59.8 million in total cash and $185.1 million in non-vehicle net debt, with total available liquidity of $185.7 million [15] - Cash flow from operating activities was $4 million for the first half of 2025, a significant decrease from $29 million in the same period of 2024 [15] Q&A Session Summary Question: Current pricing environment for new and pre-owned vehicles - Management noted that the industry seems to have stabilized, with signs of an upward trajectory in pricing for both new and pre-owned vehicles [21][22] Question: Update on Wholesale Express and rebuilding the sales force - Management indicated a reset approach, focusing on relationship-driven business and exploring new B2C opportunities, while acknowledging challenges in finding the right brokers [25][26]

Financial Data and Key Metrics Changes - For Q2 2025, revenue grew 15% to $344.3 million, driven by solid low double-digit organic growth and contributions from recent acquisitions and greenfields [22] - Adjusted EBITDA was $25 million, up 15% year over year, with margins holding steady at 7.2% [23] - Adjusted EPS came in at $0.23, and the company maintained adjusted EBITDA margins at 7.2%, consistent with the prior year [6][22] - Cash position increased by approximately $4.8 million from Q1, ending the quarter with $18.8 million in cash [23] Business Line Data and Key Metrics Changes - Resident count increased 12% to over 195,000 [22] - The company added three new pharmacies this quarter, two via acquisition and one greenfield startup [9][10] - The recent acquisitions and greenfield startups are expected to account for a high single-digit percentage of 2025 revenue but will not contribute to EBITDA for the full year [26][27] Market Data and Key Metrics Changes - The company is expanding its presence in high-growth markets, including a new pharmacy in Naples, Florida, and acquisitions in Kansas and Washington [9][10] - The company anticipates typical seasonality in Q4 driven by COVID and flu vaccine activity, which turned profitable last year [24] Company Strategy and Development Direction - The company is focused on disciplined expansion into attractive high-growth markets and views M&A as an attractive use of capital [7][10] - The company is committed to operational excellence and customized service tailored to the communities served [10] - The long-term growth thesis remains intact, with a focus on organic growth, strategic greenfield opportunities, and a robust acquisition pipeline [21][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in funding future growth with internally generated cash and highlighted the strong year-to-date performance [6][7] - The company is proactively addressing changes in the policy environment, particularly regarding the Inflation Reduction Act and its impact on drug pricing [14][15] - Management remains optimistic about the ability to resolve pricing challenges and is engaged in constructive discussions with PBMs [18][19] Other Important Information - The company completed a non-dilutive secondary offering, nearly doubling its public float and improving trading dynamics [13] - The company recorded $1.1 million in costs associated with being a public company that did not exist in the prior year quarter [23] Q&A Session Summary Question: Is the vaccine program at a steady state or is there still potential for growth in Q4? - Management indicated that the vaccine program is at a steady state with general growth of the overall business [33] Question: When do PBM negotiations typically conclude? - Management stated that they are making good progress in negotiations and will update guidance as they approach Q4 [34] Question: Has being a public company changed the prospects or visibility of the company? - Management noted that increased visibility in public markets is a strong affirmation of the company and its services [36] Question: Can you elaborate on the organic growth drivers? - Management highlighted that organic growth is driven by share gain, patient acuity, and more complex drug regimens [43] Question: What is the current state of the acquisition pipeline? - Management confirmed that the acquisition pipeline remains strong, with human capital being the main limiting factor [44][45] Question: Can you provide figures on the recent managed healthcare pharmacy acquisition? - Management described the acquisition as typical in size and expressed excitement about the leadership team and market opportunities [48] Question: What is the expected resident count by the end of Q3? - Management indicated that they will continue the organic growth trajectory and layer in the impact of recent acquisitions [57]

Financial Data and Key Metrics Changes - Q2 2025 revenue was $234.9 million, representing a year-on-year growth of 2.5% or 1.8% on a currency neutral basis [4][12] - Adjusted EBITDA for the quarter was $68 million, down 1.2% reported and 2.2% on a currency neutral basis [4][17] - Free cash flow was negative $9.6 million compared to positive $31.1 million in Q2 2024, primarily due to cash outflows related to merger and legal expenses [19] - The company finished the quarter with $110.3 million in cash, down $11.4 million from Q2 2024 [19] Business Line Data and Key Metrics Changes - Subscription revenue accounted for 53.5% of total revenue, up from 52.9% in Q2 2024, with a growth of 3.7% or 3% on a currency neutral basis [12] - Annual subscriber count reached 321,000, representing a growth of approximately 14% over the comparable 2024 period [13] - Paid downloads decreased slightly to 93 million, while video attachment rate increased to 16.7% from 15.6% in the prior year [14] - Editorial revenue grew by 5.6% year-on-year to $88.3 million, driven by strong demand for news and sports coverage [15] Market Data and Key Metrics Changes - Revenue growth in The Americas was 7.2% on a currency neutral basis, while EMEA was down 6% and APAC down 1.1% [16] - The agency business faced challenges, with a 10% decline in Q2, impacting overall creative performance [14][11] Company Strategy and Development Direction - The company continues to focus on expanding its subscription business and enhancing its AI capabilities, which are integrated into its image subscriptions [8][9] - The merger with Shutterstock is progressing, with shareholder approval received and regulatory reviews ongoing [10][9] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and challenges in the agency business but expressed confidence in the corporate and media segments [11] - The company anticipates tougher year-on-year comparisons in the second half of 2025 due to the impacts of the Hollywood strikes and production disruptions [22][23] Other Important Information - SG&A expenses increased to $105.1 million, primarily due to professional fees related to compliance efforts and ongoing litigation [17] - Adjusted EBITDA less CapEx was $51.9 million, down 3% year-on-year [18] Q&A Session Summary Question: Comments on strength in corporate media relative to subscription results - Management indicated that the creative decline is primarily due to agency challenges, while corporate and media segments are performing well [26][28] Question: Clarification on agency weakness versus a la carte strength - Management clarified that agency weakness impacts a la carte performance, and editorial a la carte continues to perform well [32][34] Question: Drivers of subscription mix shift and retention rate increase - Management highlighted growth in e-commerce subscriptions and noted that retention rates are stabilizing, particularly in Premium Access [38][42] Question: Update on litigation with Stability AI - Management explained the strategic differences in litigation between the US and UK, emphasizing ongoing efforts in the US case [40][46]

Financial Data and Key Metrics Changes - For Q2 2025, the company reported R&D expenses of $11 million, an increase from $9.1 million in the same period last year, primarily due to higher expenses related to the PHOENIX trial and manufacturing costs [10] - G&A expenses rose to $6.5 million from $1.4 million year-over-year, mainly due to increased share-based compensation [10] - The net loss for the quarter was $16.3 million, compared to a net loss of $9.5 million in the same period last year, with a significant portion of the increase attributed to non-cash share-based compensation [11] - As of the end of Q2, the company had $149.2 million in cash and equivalents, with a projected four-year cash runway [12] Business Line Data and Key Metrics Changes - The company is advancing its drug teneraband, which is in global phase three trials for Stargardt's disease and geographic atrophy, with significant progress reported in both trials [5][6] - The Dragon trial for Stargardt's disease has completed interim analysis, and the FDA has recommended proceeding without modifications, with completion expected in Q4 2025 [7] - Enrollment for the Dragon two trial is ongoing, with 17 out of 60 subjects enrolled, including 10 Japanese subjects [8] Market Data and Key Metrics Changes - The company has received multiple designations for teneraband, including breakthrough therapy and orphan drug designations in the US, Europe, and Japan, indicating a significant unmet medical need [6] - The global phase three study for geographic atrophy has completed enrollment with 529 subjects [8] Company Strategy and Development Direction - The company aims to position teneraband as the first oral treatment for degenerative retinal diseases, focusing on completing its phase three trials and preparing for potential regulatory submissions [9] - The management is strategically expanding the Dragon two trial to additional countries to accelerate enrollment [43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing trials and the potential for accelerated approval based on interim data, with a focus on achieving robust statistical significance [17][55] - The company anticipates higher cash burn in the coming years as it approaches key clinical milestones, but expects to maintain a four-year cash runway [47] Other Important Information - The company raised $15 million in gross proceeds from a registered direct offering on August 8 [8] - Management emphasized the importance of confidentiality regarding efficacy data until the submission to the FDA [29] Q&A Session Summary Question: Status of FDA discussion regarding interim data from the Dragon trial - The company has met with the FDA and is on track to potentially file for accelerated approval based on interim analysis data, with a recommendation to complete the 24-month study [16][19] Question: Plans for interim analysis of the GA trial - An interim analysis is planned for the GA trial, but specific timelines are not yet available [22] Question: Educational efforts for the medical community - The company plans to present data at the AAO conference but will keep efficacy data confidential until submission [29][30] Question: Timeline for data release and filing - The company expects to have sufficient long-term safety data by the first quarter of next year and is on track with CMC discussions with the FDA [63][66]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 6% year over year, with underlying business revenue (excluding affected DSP and political advertising) growing 19% year over year [6][29] - Adjusted EBITDA margin was 20%, marking the 37th consecutive quarter of adjusted EBITDA profitability [6][34] - The company generated $14.9 million in net operating cash flows and $9.3 million in free cash flow during the second quarter [36] Business Line Data and Key Metrics Changes - CTV revenue grew over 50% year over year, representing approximately 20% of total revenue [29][15] - Emerging revenue streams more than doubled year over year, accounting for 8% of total revenue [29] - Display revenue was flat year over year, a significant improvement from a 10% decline in Q1 [30] Market Data and Key Metrics Changes - EMEA and APAC revenues grew 187%, while Americas revenue declined by 1% [32] - Ad spend from performance marketers and mid-tier DSPs grew over 20% year over year [12][32] - The top 10 ad verticals grew in the mid-single digits year over year, with health and fitness, technology, and travel each increasing over 20% [31] Company Strategy and Development Direction - The company is focusing on diversifying its DSP mix and accelerating investment on the buy side, particularly in CTV and emerging revenue streams [10][11] - The integration of AI across the tech stack is a priority to enhance campaign performance and operational efficiency [21][23] - The company anticipates significant market share expansion due to recent antitrust rulings affecting Google, estimating that a 1% market share shift could represent $50 to $75 million in net revenue [24][25] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a recent headwind from a top DSP partner that shifted clients to a new platform, impacting revenue in July but stabilizing in August [38][45] - The company remains confident in its strategy to diversify demand and revenue streams, despite the challenges faced [25][41] - The outlook for Q3 is conservative, with expected revenue in the range of $61 to $66 million, factoring in the impact from the DSP changes [40] Other Important Information - The company has a healthy balance sheet with $117.6 million in cash and marketable securities and zero debt [36] - The company has repurchased $178.2 million worth of Class A common shares since February 2023 [36] Q&A Session Summary Question: Can you provide details about the changes from the DSP? - Management explained that a top DSP shifted clients to a new platform that evaluates inventory differently, leading to a notable drop in spend in July, which has since stabilized in August [45][46] Question: How has the conversation with advertisers evolved with the rise of SPO? - Conversations have deepened around solving advertisers' challenges, particularly in transitioning away from cookies and focusing on performance-based solutions [53][54] Question: What is the company's view on the evolution of the industry regarding DSPs and SSPs? - The company believes the lines between DSPs and SSPs are blurring, with a shift towards end-to-end platforms driven by performance and transparency [58][60] Question: What is the current concentration of DSPs? - The top two DSPs represent about half of overall spending, with efforts ongoing to diversify the DSP mix [63]

Financial Data and Key Metrics Changes - As of June 30, 2025, the company's cash, cash equivalents, and marketable securities totaled approximately $122.8 million [23] - Revenues for Q2 2025 were zero, compared to approximately $4 million for Q2 2024, and total revenues for 2025 were zero compared to approximately $8.9 million for 2024 [23][24] - Research and development expenses for Q2 2025 were approximately $20.1 million, up from approximately $11.7 million in Q2 2024, and total R&D expenses for 2025 were approximately $36.3 million compared to approximately $21.8 million for 2024 [25][26] - General and administrative expenses for Q2 2025 were approximately $4 million, compared to approximately $1.8 million in Q2 2024, and total G&A expenses for 2025 were approximately $7 million compared to approximately $3.6 million for 2024 [26] - The net loss for Q2 2025 was approximately $25.9 million, compared to a net loss of approximately $11 million for Q2 2024, and the total net loss for 2025 was approximately $50.3 million compared to approximately $20.8 million for 2024 [26] Business Line Data and Key Metrics Changes - The company is focused on advancing daramycin for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy, which is a significant unmet need in the DMD community [5][6] - The HOPE-three trial is fully enrolled with 104 patients, and the primary efficacy endpoint has been amended to Left Ventricular Ejection Fraction (LVEF) [9][10] Market Data and Key Metrics Changes - The company is actively working with the FDA to clarify the path forward for daramycin following a complete response letter received in July 2025 [6][12] - The company is also involved in Project NextGen, focusing on advancing next-generation vaccines for COVID-19 and other infectious diseases through its Stealth X vaccine [17][18] Company Strategy and Development Direction - The company aims to deliver transformative therapies for rare diseases, with a strong commitment to the DMD community [5] - The strategy includes working constructively with the FDA to define a clear path for daramycin's approval and preparing for potential commercial launch activities [8][16] - The company is also exploring opportunities in vaccine development through its exosome platform, which could lead to partnerships and expansion into other therapeutic areas [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of their data and the potential for daramycin to stabilize cardiac function in DMD patients [14][29] - The company remains focused on regulatory clarity and is optimistic about the upcoming Type A meeting with the FDA [35][64] - Management emphasized the importance of LVEF as a primary efficacy endpoint and the need for innovative thinking from the FDA regarding rare disease approvals [82][87] Other Important Information - The company has received formal acceptance of all items from its pre-license inspection, validating its quality systems and manufacturing capabilities [14][15] - The company is well-positioned financially, with over $120 million in cash, allowing it to support operations until late 2026 [28] Q&A Session Summary Question: What is the plan for unblinding the HOPE-three trial? - The company is waiting for FDA adjudication on requirements for HOPE-three before proceeding with unblinding [33] Question: What incremental data could be submitted to the FDA? - The company is considering submitting supplemental open-label extension data to support safety and efficacy [41] Question: How has the FDA review team changed? - The company is uncertain about changes in the review team but is looking forward to working with the FDA [111] Question: What are the key takeaways expected from the upcoming Type A meeting? - The company aims to clarify what is required for approval and the primary endpoint for HOPE-three [64] Question: What accounts for the increase in R&D expenses? - The increase is due to ongoing clinical studies and preparations for CMC endeavors [105]

Financial Data and Key Metrics Changes - Total net revenue for Q2 2025 was $2.2 million, down from $3.9 million in the prior quarter and $4.2 million in Q2 2024 [20] - Product revenue in Q2 2025 was $2.2 million, compared to $3.8 million in the prior quarter and $4.1 million in Q2 2024 [20] - GAAP gross margin decreased to 48.3% in Q2 2025 from 69.3% in the prior quarter and 55.5% in the year-ago quarter [22] - GAAP operating expenses for Q2 2025 were $2.9 million, down from $3.2 million in the prior quarter and $6.8 million in Q2 2024 [22] - GAAP net loss for Q2 2025 was $1.8 million, or a loss of $0.31 per share, compared to a net loss of $0.5 million or a loss of $0.08 per share in the prior quarter [23] Business Line Data and Key Metrics Changes - Revenue from millimeter wave products was $2.2 million in Q2 2025, up from $1.5 million in the prior quarter and $0.7 million in Q2 2024, indicating a significant growth trajectory [22] - The company achieved over 2 million cumulative shipments of mmWave devices, highlighting its market leadership [6] Market Data and Key Metrics Changes - Fixed wireless access continues to be the largest and fastest-growing market opportunity for mmWave technology, driven by demand for high-speed broadband connectivity [8] - The company has seen a steady recovery in market demand and customer orders for fixed wireless access solutions throughout the first half of the year [8] Company Strategy and Development Direction - The company is focused on expanding its market presence in tactical communications and military defense applications, leveraging its mmWave technology [10] - The company aims to convert successful proof of concepts into initial production orders to sustain future growth [10][19] - The company is exploring potential strategic alternatives, including mergers or asset sales, to enhance its financial position [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growing demand for mmWave technology and its ability to address critical communication challenges in tactical defense environments [10] - The company anticipates record quarterly revenue contribution from mmWave products in Q3 2025, supported by a healthy backlog [26] Other Important Information - The company had approximately $1.8 million in cash and equivalents as of June 30, 2025, with a net change of approximately $1 million during the quarter [24] - The company is actively pursuing non-dilutive financing opportunities to strengthen its balance sheet [39] Q&A Session Summary Question: Can you provide more details on the military engagements and drone opportunities? - Management highlighted stealth communication capabilities as a key advantage in military applications, with ongoing engagements to adapt technology for drone use [32] Question: Can you confirm the legitimacy of the acquisition proposal and provide updates on the business outlook? - Management confirmed the validity of the proposal and indicated ongoing efforts to explore various capital-raising opportunities [39] Question: How is inventory trending, and have you burned through previous inventory issues? - Management noted improvements in inventory movement, with significant orders being filled and replenishment of certain products underway [41] Question: Are there opportunities for non-recurring engineering (NRE) work with the military? - Management confirmed that NRE is part of their strategy, with ongoing projects expected to lead to production and additional revenue [44][63]

Financial Data and Key Metrics Changes - Second quarter net product sales were $28.8 million, down from $30.7 million in the prior year quarter [17] - GAAP net income for the second quarter was $16.4 million compared to a loss of $3.7 million in the prior year [19] - Adjusted EBITDA for the second quarter was $5.6 million, up from $3.1 million in the prior year quarter [20] - Cash, cash equivalents, and short-term investments totaled $98.2 million as of June 30, 2025, an increase from $87.3 million as of March 31, 2025 [20] Business Line Data and Key Metrics Changes - ROLVOIDON sales were $16.1 million, up from $15.1 million in the prior year quarter, driven by higher volume and favorable returns reserve adjustment [17] - SYMPAZAN sales were $3.2 million, up from $2.7 million in the prior year period, reflecting higher volume and favorable payer mix [18] - INDOCIN sales were $3.0 million, down from $6.9 million in the prior year quarter due to expected generic competition [18] Market Data and Key Metrics Changes - Demand for ROLVOIDON and SYMPAZAN remains strong, with a nearly 20% increase in demand from Q1 to Q2 [27] - The company has finalized its third national agreement for ROLVOIDON with a leading national payer, indicating continued momentum in market access strategy [12] Company Strategy and Development Direction - The company is in the transformation phase of its three-part business strategy, focusing on actions intended to catalyze future growth potential [7] - The strategy includes reducing legal exposure, simplifying corporate structure, prioritizing investments in growth assets, and divesting non-core assets [9] - The company aims to pivot towards specialty pharma assets with long-term growth potential [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term business strategy, indicating that the company has reached an inflection point [15] - The updated guidance for net product sales is $108 million to $118 million, and for adjusted EBITDA is $11 million to $19 million [21] Other Important Information - The company has settled multiple legal matters, reducing ongoing operating costs and future uncertainty [10] - The decision to cease commercialization of OTREXUP is expected to free up resources for growth assets and improve profitability [13] Q&A Session Summary Question: Understanding ROLVOIDON sales in the quarter - Management confirmed that the true ROLVOIDON sales, after accounting for reserves, reflect a growth of 10.7% [25] Question: Market opportunities and potential deals - Management stated that they have not missed out on any significant opportunities but are being selective in pursuing deals that fit their model [28][30] Question: Guidance range and impact of generic competition - Management indicated that they will be in a better position to narrow the guidance range in November, with other strategic factors also influencing the range [32][34] Question: Remaining litigation matters - Most litigation matters have been closed, with only some shareholder lawsuits remaining [38] Question: Drivers of ROLVOIDON demand - Expanding the customer base has significantly driven demand growth, with expectations for continued growth into 2026 [39] Question: Cost savings from halting OTREXUP commercialization - Expected cost savings from OTREXUP are in the range of $2 million to $3 million, primarily from reduced marketing and PDUFA fees [45] Question: Same day dosing data impact - Increased interest in same day dosing is noted, with hopes for publication in a peer-reviewed journal this year [50] Question: Future sales levels for SYMPAZAN - Management anticipates that SYMPAZAN net sales could reach between $25 million and $30 million in the next several years [54]

Financial Data and Key Metrics Changes - The company reported net revenue of approximately $41 million for Q2 2025, exceeding guidance of $40 million and reflecting a decrease from $53.5 million in the same period last year [7][15] - Gross margins improved to 28.3% in Q2 2025, up from 26.9% in Q2 2024, driven by higher proprietary brand sales [9][17] - The net loss for Q2 2025 was $4.8 million, or negative $0.08 per share, an improvement from a net loss of $5.9 million, or negative $0.10 per share, in Q2 2024 [18] Business Line Data and Key Metrics Changes - Proprietary product sales accounted for nearly 32% of total revenue in Q2 2025, up from 21.5% in the same period last year, indicating a stronger focus on higher-margin products [8][15] - In the MMI storage solutions segment, revenue reached $8.1 million, up over 69% sequentially, reflecting strong demand and product diversification [12] Market Data and Key Metrics Changes - The company is expanding internationally, having signed a distribution agreement with V1 Solutions for commercial sales across the European Union and launched a proprietary product line in Costa Rica [11] - The company noted a significant backlog in durable goods, indicating a recovery in demand within the industry [40] Company Strategy and Development Direction - The company is focused on transforming into a leaner, more profitable, product-driven business with an emphasis on B2B customers [6] - The acquisition of Viagro is seen as a strategic move to enter the home gardening market and strengthen the proprietary brand portfolio [11][27] - The company aims to achieve gross margins in the 30% range and is actively working to mitigate tariff impacts through diversified sourcing and improved supply chain efficiency [30][33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for growth in the lawn and garden space and the positive impact of cannabis reform on the cultivation ecosystem [14][27] - The company is not providing full-year 2025 guidance due to uncertainties in global trade policy and cannabis reform but expects sequential revenue growth in Q3 2025 [20] Other Important Information - The company ended Q2 2025 with $48.7 million in cash and no debt, providing flexibility for working capital and growth initiatives [13][19] - The company is continuing to rationalize operations and expects further cost savings in the latter half of 2025 [20] Q&A Session Summary Question: Insights on the Viagro acquisition and opportunities in the gardening space - Management sees tremendous opportunity in the lawn and garden space with the Viagro acquisition, which brings strong relationships and products that can crossover into cannabis [27] Question: Future gross margin expectations amid tariff risks - Management aims for gross margins to reach the 30% range and is implementing strategies to mitigate tariff impacts while maintaining competitive pricing [30][33] Question: Status of expense reductions and future cuts - Management confirmed ongoing cost reductions and expects additional improvements in SG&A and operating expenses in the latter half of the year [38] Question: Industry outlook and capital investments - Management noted a significant backlog in durable goods and observed clients beginning to refurbish their portfolios, indicating a positive shift in industry dynamics [40] Question: Timeline for repositioning the business towards commercial focus - Management believes most internal needs are met and anticipates significant savings and growth opportunities by the end of Q4 2025 [46][48]